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Pulmonary Biosynthesis and Metabolism of
Prostaglandins and Related Substances
by Thomas E. Eling* and Ariff 1. AIIy*
On passage through the lung vascular bed, prostaglandins are removed from the circulation by a
transport carrier and subsequently inactivated by intracellular enzymes. However, PGI2 is not inactivated
by the lung in vivo. Although PGI2 is an excellent substrate for the intracellular enzymes in vitro, PGI2 is
not a substrate for the carrier system. Thus, the transport carrier determines which circulating
prostaglandin is inactivated by the pulmonary vascular bed. Also, the lung has a high capacity for forming
prostaglandins from arachidonic acid. Considerable differences exist between species in relation to amount
and specific prostaglandin formed as determined by incubation of11C-PGH2 with pulmonary microsomes.
The pulmonary biosynthesis and metabolism ofthese prostaglandins and related substances are discussed.
It has longbeen recognized that the lungs have ahigh
capacityforinactivatingcirculatingbioactive substances.
The early work ofVane and his colleagues (1) indicated
thatthecirculatingprostaglandins (PGs) areextensively
inactivated on single passage through the pulmonary
circulation. It was subsequently shown (2) that the lung
is particularly rich in two enzymes, 15-hydroxy pros-
taglandin dehydrogenase (PGDH) and 13,14-reductase,
thatdegradate PGs. Thus, it islikelythatthelung orits
pulmonary vascular bed is a major site for the inac-
tivation of PG present in the circulation.
Other studies have shown that the lung is also rich in
enzymes that convert arachidonic acid into PGs and
related substrates. In response to a variety of stimuli,
both physiological as well as pathological, PGs and
related substrates are released into the circulation.
Recently, it has been proposed by Gryglewski et al. (3)
that the vascular bed ofthe lung continuously secretes
PGI2 into the circulation and that the lung acts as a
natural defense against development of intra-arterial
thrombus. Thus, the lung appears to be a unique organ
that controls or maintains the levels of a particular
circulating prostaglandin.
a keto group by prostaglandin dehydrogenase (PGDH)
followed by reduction of double bond at C-13 by A13
reductase (Fig. 1). This is accompanied by biological
inactivation (4). The enzymes have been purified and
extensively studied. PGE1 is the best substrate having
lowest Km and highest Vmax but PGE2, PGF1,, PGA1,
and PGA2 were also substrates with higher Km values
and lower Vmax (5). With the discovery of PGI2 and its
nonenzymatic breakdownproduct6-keto-PGF1o byVane
and his colleagues (6) and the potential biological
importance of PGI2, the question of the metabolism of
thisprostaglandinbyPGDH arose. Wehaveinvestigated
the metabolism of PGI2, 6-keto-PGF1I and PGF2a by
rat lung 600 g supernatant fortified with NAD+.
Incubation of rat lung homogenates with 3H-PGF2a
resulted in the formation of two distinct metabolite
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Metabolism by Lung Subcellular
Fractions in Vitro
Studies on the metabolism of prostaglandins in lung
tissue indicate that PGs undergo metabolic transfor-
mation. First, the hydroxyl group at C-15 is oxidized to
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FIGURE 1. Metabolism ofprostaglandin by lungprostaglandin dehy-
drogenase and reductase.ELING AND ALLY
peakswhich cochromatographed with authentic 15-keto-
PGF2a and 13,14-dihydro-15-keto-PGF2a. As found
previously, the rat lung seems to lack the 15-keto-
prostaglandin reductase that is necessary for formation
of the 13,14-dihydro-PG metabolites (7).
Two chromatographic peaks resulted from the in-
cubation of 3H-PGI2 or 3H-6-keto-PGF,o with rat lung
homogenates. The peak remaining closest to the origin
cochromatographed with both 6-keto-PGF1a, the break-
down product ofPGI2, and 6-keto-13,14-dihydro-PGF10,.
The peak closest to the solvent front could be either
6,15-diketo-PGF1a or 6,15-diketo-13,14-dihydro-PGF1o
or a mixture ofthese metabolites. Further attempts to
separate these metabolites by means of other TLC
systems were unsuccessful. However, Wong et al. (8)
have recently used GC-MS to isolate and identify
6,15-diketo-PGF1a as a major metabolite formed from
incubation of PGI2 with the cytoplasm of various blood
vessels. The major metabolite formed in our incubation
system was, therefore, most likely to be 6,15-diketo-
PGF1a. Since PGI2 is relatively stable at pH used in the
incubation, we conclude that the 6,15-diketo-PGF1a
found in this incubation system probably arose from
nonenzymatic hydrolysis of 15-keto-PGI2 during the
workup procedure.
PGI2 and PGF2o appeared to be metabolized to
comparable extents by rat lung homogenates over a
10-min incubation period (Fig. 2). After 4 min 16% of
both the PGF2a and PGI2 was degraded, while after 10
min, 41% of the PGF2a was metabolized compared to
35% ofthe PGI2 (7). In contrast, 6-keto-PGF1a was only
minimally metabolized (6% at 10 min). Little or no
metabolism (- 2%) ofany PG was obtained with boiled
homogenates.
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McGuireand Sun(9)haveinvestigatedthemetabolism
of PGI2 by a partially purified prostaglandin dehydro-
genase obtained from rhesus monkey. These workers
also found that PGI2 but not 6-keto-PGF1a was an
excellent substrate forPGDH. PGI2was oxidized at4to
6 times faster than 6-keto-PGF1a. The km for PGI2 was
found to be 7.4 ,uM compared to 14.5 ,uM for PGE1 and
56 ,uM forPGF2a. These dataindicate that PGI2but not
6-keto-PGF1a is the physiological substrate for pul-
monaryPGDH. The sequence ofPGI2metabolism is the
formation of 15-keto-PGI2 followed by nonenzymatic
breakdown to 6,15-diketo-PGI1a (Fig. 3).
Studies on the Transport of PG by
Pulmonary Tissue
The early work ofVane and his asociates showed that
prostaglandin E1, E2 and F2a were rapidly and exten-
sively inactivated in a single passage through the lung
vasculature (1). Reports from various investigators
reveal no species variation in the inactivation of PGE
and PGF2a from the circulation by the lung. Cat, dog,
rabbit (1) and rat (10) lungs have all been shown to
inactivate PGE and PGF2a from the pulmonary circu-
lation. However, guinea pig (11) and rabbit (12) isolated
perfused lungs (IPL) have been shown to metabolize
A-type PGs, while cat (13), dog (14), and rat IPL (10)
have not. PGA1 appears to be a substrate for the
intracellularprostaglandin dehydrogenase (PGDH) (15).
Thus, the species differences in metabolism may be the
result of a species difference in accessability to the
intracellulardegradativeenzymes. Thesefacts, together
with the rapidity ofthe processes, suggested to us that
a carrier or a transport system was responsible for the
rapid removal of PGs from the circulation and that the
transport system imparts selectivity to the pulmonary
inactivation system.
In order to study the removal mechanism, measure-
ment ofthe initial velocity or unidirectional flux ofPGs
from the perfusate into the intact lung cells was
necessary. We therefore used an isolated perfused rat
lung preparation which permitted measurement of the
initial velocity at a constant concentration ofPG in the
arterial perfusate. Previously published work details
the specifics of the measurements (10).
The initial velocity ofPGE1 uptake into the lung was
saturated withincreasingconcentrations ofPGE1 in the
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FIGURE 2. Metabolism of3H-PGI2, 3H-PGF2 and 3H-6-keto-PGF,a
by rat lung homogenate.
FIGURE 3. Pathway forthe metabolism ofPGI2 and 6-ketoPGF1l by
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perfusate (Fig. 4). This type ofrelationship between the
initial velocity and the perfusate concentration suggests
that a carrier-mediated or transport process was
involved in the removal of PGE1 by the lung. Diffusion
or binding of the PG to lung tissue would give a linear
relationship between the initial velocity and perfusate
concentration.
We have also examined the rates of removal of
PGF20, PGB1, PGA1 and 15-keto-PGF20 from the
vasculature to the lung. Both removal and metabolism
was observed with PGF2a. This suggests that definitive
substrate specificity exist for the carrier molecule.
PGA1 is metabolized in vitro by lung PGDH. However,
the PGA1 metabolism is not observed in vivo. This may
be explained by the fact that PGA1 is not a substrate for
the carrier molecule. Further support for the existence
ofa carrier ortransport system in rat lungwas obtained
by inhibitor studies. The addition of a second PG
substrate for example, PGF2a, significantly inhibited
the removal ofthe first substrate PGE1. The addition of
a nonsubstrate, i.e., PGA1 did not inhibit the removal of
the substrate PGE1 for the transport system. Further
studies showed that PGF2a competitively inhibited the
uptake of PGE1. Thus, saturation ofthe initial velocity
with respect to perfusate concentration, the inhibition
ofthe removal ofone PG by another, and the concentra-
tion dependence ofthis inhibition, support ourhypothe-
sis of a transport system.
The substrate specificity for the inactivation of
circulating PGs appears to reside with the transport
carrier since both PGE1 and PGF2a are removed, but
PGA1 and 15-keto-PGF2a are not removed from the
circulation. We have studied the structural requirement
of the PG molecules essential for transport from the
Dependence of pulmonary removal of PG on the concentration
of PG in the perfusate.
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FIGURE 4. Saturation of PGE1 uptake velocity with perfusate
concentration.
circulation into the lung. As seen in Table 1 (16), PGE1,
PGE2, PGF,a, PGF201, PGF2p and to some extent PGD2
and PGD1 were removed from the circulation into the
lung. PGA1, PGB1 and various metabolites of the
classical PGs were not removed. In addition, the methyl
esters of PGs were not substrates for the transport
system. With the discovery of PGI2 and its potential
importance in controlling intra-arterial thrombosis, it
was important to determine ifPGI2 was a substrate for
the transport system. Studies with in vitro incubation
systems (see above) indicate that PGI2 was an excellent
substrate for pulmonary PGDH. However, using bio-
assay techniques, Dusting et al. have studied the
disappearance ofPGI2 in the circulation ofthe dog (17).
Their work indicated little or no inactivation ofPGI2 on
passage through the lung, while extensive inactivation
occurred in the liver and hind quarters. Similarly, the
conclusion that PGI2 escapes pulmonary metabolism
has been reached by Bolger and co-workers while
studying the renal actions of PGI2 (18), and by
Armstrong et al. in a study of hypotension induced by
PGI2 (19). The data suggest that PGI2 is not a substrate
for the carrier system. Since PGI2 was not stable at pH
7.4, determining the removal of PGI2 from the circu-
lation into the lung required a different experimental
approach than measurement of the initial velocity.
Uptake was studied by indicator dilution techniques.
The effluent from an isolated rat lung was collected in
approximately 1-sec intervals after injection ofa 3H-PG
and the vascular marker 14C-dextran. For PGF20 (a
transport substrate), analysis of the effluent radio-
activity showed a displaced tritium peak indicating that
the PGF20a was taken into the vascular cells (Fig. 5a).
Analysis ofthe effluent indicated that the3H-PGI2a was
extensively degraded. However, after bolus injection of
3H-PGI2 or 3H-6-keto-PGF1a mixed with 14C-dextran,
analysis ofthe effluent indicated the mean transit times
for both PGI2 and 6-keto-PGI1a (Fig. 5a) were identical
to the vascular marker dextran. Furthermore, neither
PGI2 nor6-keto-PGF1o was metabolized duringpassage
through the lung. Thus, PGI2 and 6-keto-PGF1o are not
Table 1. Uptake of PG by rat lung.
3H-PG Uptake velocity (relative to PGEI)
PGE1 1.0
PGE2 0.86
PGF1. 0.68
PGF2. 1.20
PGF23 1.0
PGA1 0
PGB1 0
PGD2 0.57
PGD1 0.25
15(S)methyl-PGF2 1.45
15(R)methyl-PGF2 0
15-keto-13,14-dihydro-PGE1 0
13,14-dihydro-PGE, < 0.2
13,14-dihydro-PGF2 < 0.4
PG methyl esters 0
15-epi-PGE2 0
15-epi-PGF2 0
Km
a 3.23 ± .35 (nmole/sec)
- V/x a2.6t.15 (nmole/sec/organ)
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FIGURE 5. Appearance ofradioactivity inthe effluentofratperfused
lung after a bolus injection of 3H-PG and 14C-dextran: (a) ( )14
dextran, (- -) 3H-PGF2. and metabolites; (b) ( ) 14C dextran,
(-_-) 3H-PGI2 or 3H-6-keto-PGF1.
substrates for the transport system; thus, the biological
half-life ofPGI2 is not controlled by passage through the
pulmonary vascular bed.
The present studies (7,10,16) show there are appar-
ently three critical portions (Fig. 6) ofthe PG molecule
necessary for transport into lung tissue: the acid group
at C-1, the oxygen function, particularly a hydroxyl
group at C-il, and a hydroxyl group at C-15 in the S
configuration. The steric relationship between these
groups is important since reduction of the 13,14-double
bond reduces or abolishes transport, and changing the
C-15 hydroxyl group from S to R configuration abolishes
transport.
Evidence for the importance of the acid group was
derived from the observation that the methyl esters of
PGE1, PGE2, and PGF20 were not taken up into the
perfused lung. In contrast, the methyl esters of PGs
are substrates for lung prostaglandin dehydrogenase
(PGDH) (15). The importance of an oxygen function at
C-11 was illustrated by the lack ofuptake observed for
PGA1 and PGB1. The presence of a carbonyl group
(PGD2 and PGD1) rather than a hydroxyl group reduces
/COOH
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FIGURE 6. Structural requirement for pulmonary transport of
prostaglandins: R1 = hydroxyl, either a or , configuration, or
carbonyl group; R2 = hydroxyl or carbonyl group; R3 = H or CH3
in I8 configuration.
uptake by the rat isolated perfused lung. The presence
of a hydroxyl group at C-15 appears to be an absolute
requirement for removal ofPGs from the circulation by
the lung. Conversion of the hydroxyl group to a keto
group abolishes uptake. Moreover, the configuration of
the C-15 hydroxyl group is critical. 15(R) methyl-PGF2a
was not removed from the circulation by the lung,
whereas approximately 90% ofthe 15(S) methyl-PGF2a
was removed. In addition, the 15-epi isomers of PGE2
and PGF2a did not inhibit the removal of PGE1.
Alteration of the functional groups at C-9 does not
affect the removal. PGF2,s, which has a hydroxyl group
at C-9 and PGE2, with a keto group at C-9 are
substrates for the transport system. Therefore, chang-
ing the hydroxyl group at C-9 from an a to a ,
configuration had little effect. However, since PGI2
contains a ring structure between the 6 and 9 carbon
atoms, the position of the side chain containing the
carboxylic acid moiety is significantly altered in relation
to the rest ofthe molecule. In 6-keto-PGF1a a hemiketal
ring between the keto group at C-6 and the hydroxyl at
C-9 can be formed. The conditions that govern the
equilibrium between the open and closed forms are not
known. In the closed form of 6-keto-PGFja the hemi-
ketal ring significantly alters the position ofthe carbox-
ylicside chain. Inthe openform, theplanarconfiguration
of the carbonyl group may change the position of the
side chain, modifying the PG hairpin structure. An-
other possible explanation for the lack of uptake of
6-keto-PGF1a is that the presence of an additional
oxygen molecule may change the electronic characteris-
tics ofthis PG, subsequently altering the binding to the
transport carrier. Thus, the geometric configuration of
the C-1 carboxyl group in relation to the C-15 hydroxyl
group and the C-11 oxygen function is different in PGI2
and 6-keto-PGF1a compared to that of other PGs. Our
presentresults indicate that the three functional groups
on the PG molecule that are necessary for transport
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into lung tissue may need to form a precise geometric
configuration in order for transport to occur.
An alternative explanation for the lack ofpulmonary
transport of PGI2 and 6-keto-PGF1o may involve the
oxygen function at C-9. In PGI2 and the hemiketal form
of6-keto-PGF1a, the oxygen function becomes part ofa
ring system. This points to the possibility that the
presence of a free hydroxyl or carbonyl group at C-9 is
an additional requirement for pulmonary transport of
PGs. It could, therefore, be the difference in geometric
configuration and/or the lack of a free oxygen function
at C-9 that prevent PGI2 and 6-keto-PGF1a from being
transported into lung tissue.
Thus, the pulmonary inactivation system consists of
trnasport carrier and intracellular enzymes as shown in
Figure 7. The selectivity ofthe transport system in the
lung and hence the selectivity of the pulmonary
inactivation of PGs may have important physiological
significance. The pulmonary removal and inactivation of
some PGs may serve to protect the arterial circulation
from potentially deleterious effects ofthese PGs. Since
PGI2 presumably exerts beneficial effects including
inhibition of platelet aggregation (19) and has been
implicated in the prevention ofarterial thrombosis (6), it
would be disadvantageous for it to be removed during
passage through the pulmonary bed. Recent studies (3)
have, in fact, shown that the lung in vivo actually
generates PGI2, and it has been proposed that PGI2
may be a circulating hormone (20), although some evi-
dence exists to the contrary. Thus, the lungmay play an
important role in the prevention ofarterial thrombosis.
Inhibition of Pulmonary Inactivation
The addition of various chemicals or drugs to the
perfusate altered the rate ofremoval and/or rate ofPG
metabolism by the lung. Several PG antagonists,
FIGURE 7. Schematic diagramofthepulmonary inactivation system.
polyphloretin phosphate (PPP) and diphloretin phos-
phate (DPP) were effective primarily by inhibiting the
transport system (4). The organic acid transport
inhibitor, bromocresol green, was a potent inhibitor of
the transport system (16). The exposure of lung to
various environmental pollutants significantly affected
the pulmonary inactivation of circulating PGs. Bakhle
et al. (21) recently investigated the effect of cigarette
smoke on the metabolism ofvasoactive hormones by the
rat isolated lungs and reported that exposure to smoke
decreased the inactivation of circulating PGE2.
We have examined the effect ofexposure ofguineapig
and rats to the environmental gases, NO2, SO2 and 02
(22). As measured by in vitro assay techniques, prosta-
glandin synthetase was not altered by the exposure.
However, exposure to 02 and NO2 but not SO2 sig-
nificantly depressed PGDH activity. Exposure of ani-
mals to 100% 02 depressed PGDH (in vitro) with the
degree ofinhibition dependent onthelength ofexposure.
After 72 hr of 02 exposure, PGDH was depressed by
approximately 80%. Exposure ofguinea pig to 100% 02
did not apparently alter the transport carrier for PGs in
the lung. Kinetic analysis suggested that exposure of
the oxident gases resulted in destruction ofPGDH (23).
Cyclo-oxygenase Metabolism of
Arachidonic Acid by the Lungs
Prostaglandins have received the attention of pul-
monary researchers and physicians for a number of
reasons: their interaction by the lungs, their contractile
effects on bronchial smooth muscle, and their mixed
actions on the pulmonary circulation (24). In recent
months other arachidonic acid metabolites, the leuko-
trienes, have begun to attract similar interests (25).
In the future a complete understanding of the
interdependence and interactions among the prosta-
glandins, thromboxanes, and leukotrienes may provide
new thoughts into the phenomena of immediate hyper-
sensitivity reactions and could be of particular impor-
tance in the etiology of human asthma. In this section
someaspectsoflungprostaglandinbiosynthesis, species
variation and the use of microsomal preparation to
study endoperoxide metabolism will be discussed. The
metabolic pathway of arachidonic acid in mammalian
cells is summarized in Figure 8, and the detailed
biochemistry has been reviewed by Samuelsson et al.
(26).
The precise biochemical or pathophysiological factors
which lead to abnormal biosynthesis ofprostaglandins,
prostacyclin and thromboxane by lung tissue are not
well understood. A wide variety of stimuli which
presumablylead tomembrane perturbation may initiate
prostaglandinbiosynthesis. Thesestimulicanbebroadly
categorized intoanaphylaxis, chemical orenvironmental
agents and physical stimuli (27).
There is an abundance of literature dealing with the
production of thromboxane A2, SRS-A and prosta-
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FIGURE 8. Pathways of arachidonic acid metabolism.
glandins in the guinea pig lung. However, the data for
other species are sadly deficient. In 1965, Anggard (28)
described the biosynthesis of PGs from endogenous
substrate using lung homogenates of human, monkey,
sheep and guinea pig by utilizing GC-MS analysis. Of
these four species, human, rat and monkey produced
significantly lower amounts of PGF2a than guinea pig.
A large number of compounds produced from endo-
genous arachidonic acid in guinea pig lung have been
conclusively identified by Dawson et al. (29). These are
TXB2, PGE2, PGF2cx, 15-oxo-PGE2, 15-oxo-PGF2a,
15-oxo-13,14-dihydro-PGE2, and 15-oxo-13,14-dihydro-
PGF2a identified in the effluent from isolated perfused
normal guinea piglungs. In addition, 6-keto-PGF1a (the
spontaneous hydrolysis product of prostacyclin PGI2;
Fig. 8) and a novel oxodihydro derivative ofTXB2 were
seen only in sensitized lungs during anaphylaxsis.
Human lungs have bene reported to produce 6-keto-
PGF1,c in vivo (30) and PGE1, PGE2 and PGF2o and
RCS(TXA2) in vitro (31). Recently, Palonek et al. (32)
provided evidence for the spontaneous and angiotensin-
induced release ofPGI2 from cat lungs, using PGI2 anti-
bodies and a PGI2 tendon bioassay, while Veolkel et al.
(33) described the release of PGI2 during angiotensin
stimulation of rat lung in vitro. Recently, using PGI2
antibodies, Pace-Asciak et al. (34) obtained data in vivo
that argued against the notion that blood PGI2, exerts
an antihypertensive action in spontaneous hypertension
(29). Thus, it is still unclear whether PGI2 is con-
tinuously secreted into the circulation in concentrations
sufficient to exert biological effects. In sheep, Frolich et
al. (35) found that lymph provided a better index oflung
tissue prostaglandin biosynthesis. During endotoxin-
induced pulmonary hypertension, blood prostaglandin
and TXB2 levels sampled from both the left atrium and
the pulmonary artery were unchanged. In contrast, a
dramatic 400-fold increase in TXB2 concentration was
seen in lymph using both RIA and GC-MS analysis.
Enhanced lipid peroxidation has been shown to occur
in vivo in the lung following exposure to oxidant gases.
Exposure to ozone, nitrogen dioxide (36) and oxygen
(37) leads to an increase in lung lipid peroxidation.
These oxidant gases have been reported to inhibit
pulmonary prostaglandin metabolism (23). Recently,
Crutchley et al. (38) reported an increase in the release
ofTXB2, 6-keto-PGF1a, PGE2 and PGF2, as a result of
inhibition ofPGDH by exposure to 100% oxygen. These
observations may be related to the phenomenon of
increased lipid peroxidation reported by others. Oxygen
(5-95%) has been shown to stimulate prostaglandin
biosynthesis in tissue slices (39), which suggests a
direct effect unrelated to the generation ofreactive free
radicals or inhibition of 15 hydroxyprostaglandin dehy-
drogenases.
Rat lung homogenates synthesize predominantly
PGI2 (40), while guinea pig lung homogenates syn-
thesize primarily TXB2 (41). The dominance ofTXB2as
the major arachidonate metabolite in the guinea pig has
been established using lung homogenates (41) and
isolated perfused lung (41-44). Earlier, Parkes and
Eling (45) identified a novel arachidonic acid metabolite
in guinea pig lung microsomes, which has now been
named TXB2 (46) and is formed by spontaneous
hydrolysis of the parent TXA2 (see Fig. 8).
In a comparative study of 1-14C-arachidonic acid
metabolism in isolated perfused lung of guinea pig, rat
and man, Al Ubaidi and Bakle (47) found that the rat
lung provides a better model than guinea pig lung for
arachidonic acid metabolism in human lung. A similar
conclusion was reached in a study of slow reacting
substance of anaphylaxis in rat, mouse, guinea pig and
man (48).
There is no doubt that adult lungs biosynthesize
TXB2; it appears that fetal bovine and rabbit lungs
produce little TXB2 (49). In the third trimester, the
biosynthesis of PGE2 by fetal lung of both species
increased steadily with little change in either TXB2 or
PGF2'x. Interestingly, a small amount of6-keto-PGF,ox
was seeninrabbit but notbovine fetallung. In contrast,
fetal lamb produced equal amounts ofPGE2, PGF2o and
TXB2. In an earlier study, Pace-Asciak (50) found that
in very young fetal lamb, PGF20 was the dominant
prostaglandin with PGE2 increasing with gestational
age until atterm, it equaled PGF2a. In this latter study,
TXB2 was not assayed. Therefore, it appears that fetal
lung prostaglandin biosynthesis is a heterogeneous in
terms of product and amounts as it is in adult animals.
Thus, clear species and age differences exist in lung
prostaglandin biosynthesis.
Prostaglandin Synthesis by
Lung Microsomes
In experiments using lung microsomes, Tai et al. (51)
found that 14C-arachidonic acid was metabolized by
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sheep lung microsomes primarily to TXB2 (14%) and
6-keto-PGF1o (5%); with the inclusion of glutathione,
PGE2 became the major metabolite formed. Sun et al.
(52) reported that rabbit lung microsomes synthesize
both 6-keto-PGF1a and TXB2 from PGH2. As the
concentration of PGH2 is increased, the production of
6-keto-PGF1a plateaus while TXB2 increases in a linear
fashion. These data suggest that PGI2 synthetase is
readily saturated while thromboxane synthetase is not.
Thus, if large quantities of endoperoxide are produced
in pathophysiological states, TXA2 may become the
dominant product in species which normally produce
small amounts ofTXA2, e.g., rat and man, detected as
rabbit aorta contracting substance (46). In their studies
with human lung microsomes, Sun et al. (52) were
unable to demonstrate endoperoxide metabolism by
thromboxane synthetase.
In other studies with porcine lung microsomes, Tai et
al. (53) found that '4C-PGH2 was metabolized to
predominantly TXB2. Pyridine (10mM) inhibited TXB2
synthetase, resulting in an increase in the synthesis of
both 6-keto-PGF1o and PGE2, without an overall de-
crease in total product formation. We have found that
tranylcypromine (20 jig/mL) inhibits the production
6-keto-PGE2 from the endoperoxide PGH2 by porcine
lung microsomes with a significant increase in the
synthesis of both TXB2 and PGE2 (Ally and Eling,
unpublished data). Thus, the inhibition of enzymes in
the prostaglandin cascade produces a significant shift in
product formation. It is possible that some form of
negative feedback inhibition is responsible since PGE2
has been reported to inhibit PGI2 biosynthesis in rat
liver endothelial cells (54).
The heterogeneity oflungarachidonic acid metabolism
observed in different species (discussed above) is
reflected at the subcellular level. As shown in Figure 9,
the metabolic profile for 1-14-C-PGH2 in guinea pig lung
microsomes analyzed by HPLC (55) is quite distinct
from that in rat lung microsomes; the guinea pig
produces little 6-keto-PGF,a but greater than 40% of
the total products is TXB2, whereas rat appears to
make equivalent amounts of 6-keto-PGF1a and TXB2.
In experiments using 1-14C arachidonic acid and guinea
piglungmicrosomes, TXB2represented 28% and6-keto-
PGF,a 6.1% of the cyclooxygenase products. Thus, in
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FIGURE 9. HPLC profile of metabolites of PGH2 by (a) rat and (b)
guinea pig lung microsomes: (a) rat, (1) 6-keto-PGF1., (2) TXB2,
(3) PGF2., (4) PGE2, (5) PGD2, (6) HHT; (b) guinea pig, (1)
6-keto-PGF1., (2) TXB2, (4) PGE2, (5) HHT.
our experiments the arachidonic acid metabolic profile
is similar, both qualitatively and quantitatively, to that
obtained using the endoperoxide PGH2.
As shown in Table 2 human lung microsomes make
equivalent amounts of 6-keto-PGF1a and TXB2 while
PGE2 is the majorproduct. Ofthese five animal species,
the guinea pig least resembles the human prostaglandin
profile, while the rat and mouse appear quite similar.
The 6-keto-PGF1a/TXB2 ratio in human lungs is close to
unity and this ratio is seen in the porcine, bovine, rat
and mouse lung. Interestingly, mouse lung makes as
much PGE2 from PCH2 as does human lung.
These data, if representative of the extrapulmonary
Table 2. PGH2 metabolism by lung microsomes.a
Product, % of total radioactivityb
Species 6-Keto-PGFja TXB2 PGF2- PGE2 PGD2
Humanc 14.7 ± 1.4 17.9 ± 4.2 12.9 ± 0.9 23.1 ± 2.6 14.6 ± 1.2
Porcine 25.3 ± 2.8 21.9 ± 3.7 5.1 ± 1.7 6.3 ± 0.6 4.1 ± 1.1
Bovine 26.0 ± 2.0 26.0 ± 1.0 4.0 ± 1.0 3.4 ± 1.7 ND
Rat 23.0 ± 5.0 19.0 ± 3.2 9.0 ± 0.0 16.0 ± 1.0 5.0 ± 1.0
Guinea pig 3.0 ± 0.6 43.0 ± 2.0 2.0 ± 1.0 3.0 ± 1.0 ND
Mice 10.2 ± 1.2 7.1 ± 0.8 4.4 ± 0.5 23.4 ± 3.4 7.4 ± 0.3
a Analysis by HPLC-radiometric procedure.
b Values are means ± SD, N = 4; ND = not detectable.
' Macroscopically normal lung samples obtained from patients undergoing resection for cancer.
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prostaglandin profile in the lung, suggest that the
bronchioles and other nonvascular lung elements are
typically exposed to a wide range of prostaglandins, of
which two (PGI2, PGE2) have been shown to be
bronchodilators and three (TXA2, PGD2 and PGF2a) to
be bronchoconstrictors. It is suggested that alterations
in this balance together with abnormal levels of
lipoxygenase products may be responsible for respira-
tory distress in lung disease (3).
These data discussed here suggest that lung paren-
chymal microsomes may provide a clear picture of
biochemical changes in the prostaglandin and hydroxy
fatty acid profiles in pathophysiological conditions of
unknownetiologyorexposuretoairborneenvironmental
pollutants. Ofthe five animal models examined, the rat
appears to be a good choice for further studies since its
prostaglandin profile is similar to man and it has the
added convenience of being readily available, inexpen-
sive and manageable.
Lung Thromboxane and
Prostaglandin Secretion
Gryglewski and colleagues (3,56) have proposed that
the lung continuously secretes PGI2 into the circulation.
The lung is highly vascularized and has large numbers
ofendothelial cells which are highly active in producing
PGI2. Control of PGI2 release from the lung is not
understood. We have found (57) using the isolated
perfused rat lung, that PGI2 measured by RIA of
6-keto-PGF1a and TXA2 measured by RIA ofTXB2, are
continuously released into the perfusate. The concen-
tration ofTXB2 was approximately 1/5 that ofthe PGI2
detected by RIA of6-keto-PGF1a (6 ng/min TXB vs. 33
ng/min). Increasingthe rate ofrespiration increased the
release ofbothTXA2 and PGI2, but PGI2release appear
to be preferentially stimulated. At normal respiration
rate (50/min) the ratio of 6-keto-PGF1a to TXB2 was
5:1, but at 100/min the rate increased to 11:1 (Fig. 10).
Thus, measurement ofPGI2 in perfusate or blood could
be highly variable dependent, in part, on the rate of
respiration.
There is evidence for considerable species differences
in the secretion of PGI2 and TXA2 by lung. Alabaster
(42) found that guinea pig lung metabolized infused
PGH2(800ng) toprimarilyTXA2 (101 + 13ng) and PGI2
(10-16 ng), whereas in rabbit lung effluent only
unmetabolized PGH2(46 + 9ng)and somePGE2(26 + 10
ng) were detected. The PGE2 seen may represent a
spontaneous decomposition product from PGH2. Simi-
larly, Boyd and Eling (62) reported that rat lung
significant amounts of PGI2 but guinea pig produces
only very small amounts of PGI2 from PGH2 whereas
guinea pig lung was found to make primarily, TXA2.
However, guineapigplatelets appeartobe verysensitive
to PGI2.
It is now apparent that differences among the species
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FIGURE 10. Effect of respiration rate on the release of TXB2 and
6-keto-PGF1 by rat perfused lung.
may be identified pharmacologically. Indomethacin
infused into guinea pig and rabbit pulmonary vascular
beds produced qualitatively dissimilar effects on bio-
assayible products of arachidonic acid metabolism (42).
In guinea pig lung, low concentrations ofindomethacin
(10 mM) preferentially inhibited primary prostaglandin
formation without affecting TXA2 production. In rabbit
lung, this same indomethacin concentration prefer-
entiallyinhibited TXA2biosynthesis. Inbothguinea pig
and rabbit, indomethacin at higher concentrations
inhibited the biosynthesis ofallprostaglandins. Inthese
studies, Alabaster (42) found that rabbit thromboxane
synthetase was very sensitive to inhibition by imidazole
(50 i.aM). In contrast, guinea pig thromboxane syn-
thetase required 50 to 100-fold higher concentrations of
imidazole for an equivalent effect. However, inhibition
studies must be viewed with caution since inhibitors
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may have effects other than inhibition ofthe enzyme in
question and the effect may not be as easily interpreted
as presumed. For example, Hong et al. (58) found that
the PGI2 synthetase inhibitors, 15-HPAA and tranylcy-
pronine, that 15-hydroperoxy arachidonic acid (15-
HPAA) increased the release of arachidonic acid while
inhibiting the biosynthesis of prostacyclin and PGE2,
whereas tranylcypromine decreased the release of
arachidonic acid and the biosynthesis of prostacyclin in
isolated endothelial cells.
The origin ofthromboxane in the pulmonary vascular
effluent is not clear. It is generally advocated that blood
vessels do not synthesize thromboxane (26,46). It has
beenfoundthatthe ratmesenteric vascularbed secretes
both 6-keto-PGF1o (3-6 ng/min) and TXB2 (0.09-0.15
ng/min) in vitro (59); other researchers have reported
similar findings in experiments with arterial prepar-
ations of several species (59). Of particular interest is
the recent data from Salzman and co-workers (60), who
found that the rabbit intrapulmonary artery (IPA),
including the lobular artery and the extrapulmonary
artery (lying outside the lung mass), produces both
TXB2 and 6-keto-PGF1o in ratios varying from 1:2 to
1:6. In these experiments 14C-arachidonic acid was
converted by IPA to 9 + 1% TXB2 and 16 + 2% 6-keto-
PGF1m. The synthesis of TXB2 and 6-keto-PGF1a from
endogenous arachidonic acid was 100 to 200 ng/mg and
500 to 1000 ng/mg tissue, respectively, a ratio of 1:5. In
their studies a cascade of biological detectors showed
that TXA2 produced by IPA dominated the biological
responses, even though GC-MS analysis revealed five
times more prostacyclin in the incubation mixture. The
data highlight the much greater biological potency of
TXA2andindicate that smallchanges inPGI2synthesis,
such asinatherosclerosis, mayhave potentiallydramatic
biological consequences. Of particular interest is their
statement that rabbit lung parenchyma did not produce
detectable amounts of TXA2. This is surprising, since
Sun et al. (52) reported that rabbit lung microsomes
synthesize both PGI2 and TXA2 from PGH2.
It is probable that thromboxane detected in rabbit
pulmonary vascular effluent arose primarily in the
vascular compartment, since Salzman et al. (60) were
unable to detect TXA2 production by lung parenchyma,
although as noted above rabbit lungparenchymal micro-
somes contain the necessary enzyme complex. Evidence
to support the idea that nonvascular lung elements
have the capacity to synthesize both TXA2 and PGI2
has been provided by Levine and Alam (61). Using
a combined high pressure liquid chromatography-radio-
immunoassay procedure these researchers found that
endogenous arachidonic acid was metabolized to 65%
PGE2, 16% TXB2, 16% PGF2a and 4% PGI2 in normal
human lung cells, whereas rat Type II alveolar
cellsproduced 78%PGE2, 0.2%TXB2, 18.2%PGF2a and
0.7% PGI2. Such studies culturing different cell types
from the lung will in the future provide a better picture
of arachidonic acid metablism in the lung.
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